Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-squamous Cell Lung Cancer With KRAS Mutations”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Large-scale testing (Phase 3)Looking for participantsNCT06875310
What this trial is testing

Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Mirati Therapeutics Inc. 630
Testing effectiveness (Phase 2)UnknownNCT02583542
What this trial is testing

AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers

Who this might be right for
Triple-Negative Breast CancerSquamous Cell Lung CancerNon-squamous Cell Lung Cancer With KRAS Mutations+1 more
Queen Mary University of London 118
Early research (Phase 1)Study completedNCT03299088
What this trial is testing

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

Who this might be right for
KRAS Gene MutationMetastatic Non-Squamous Non-Small Cell Lung CarcinomaRecurrent Non-Squamous Non-Small Cell Lung Carcinoma+1 more
Jonathan Riess 15
Large-scale testing (Phase 3)Not Yet RecruitingNCT07822542
What this trial is testing

A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Jiangsu Hansoh Pharmaceutical Co., Ltd. 448
Testing effectiveness (Phase 2)Active Not RecruitingNCT05118854
What this trial is testing

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

Who this might be right for
Lung Cancer
M.D. Anderson Cancer Center 13
Early research (Phase 1)Study completedNCT04959981
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Erasca, Inc. 24
Large-scale testing (Phase 3)Looking for participantsNCT07777822
What this trial is testing

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

Who this might be right for
NSCLCNon-small Cell Lung CancerNon-Small Cell Lung Cancer NSCLC+4 more
Revolution Medicines, Inc. 430
Large-scale testing (Phase 3)Looking for participantsNCT06793215
What this trial is testing

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerKRAS G12C Lung Cancer
Hoffmann-La Roche 600
Early research (Phase 1)Looking for participantsNCT05504278
What this trial is testing

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd. 144
Large-scale testing (Phase 3)Not Yet RecruitingNCT06335355
What this trial is testing

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd 401
Testing effectiveness (Phase 2)Active Not RecruitingNCT06008093
What this trial is testing

Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 103
Large-scale testing (Phase 3)Not Yet RecruitingNCT07833202
What this trial is testing

Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Who this might be right for
NSCLC
Shanghai Jeyou Pharmaceutical Co., Ltd. 416
Large-scale testing (Phase 3)Looking for participantsNCT06416410
What this trial is testing

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Who this might be right for
Advanced Non-squamous Non-small-cell Lung CancerMetastatic Non-squamous Non Small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 392
Early research (Phase 1)Ended earlyNCT06585488
What this trial is testing

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Who this might be right for
Metastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung CancerAdvanced Colorectal Cancer+4 more
BeOne Medicines 47
Testing effectiveness (Phase 2)Ended earlyNCT03777124
What this trial is testing

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Who this might be right for
NSCLC Stage IVKRAS Gene MutationPD-1 Antibody+1 more
Jiangsu HengRui Medicine Co., Ltd. 25
Large-scale testing (Phase 3)Looking for participantsNCT07174908
What this trial is testing

IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Who this might be right for
Non-Small Cell Lung Cancer
InxMed (Shanghai) Co., Ltd. 400
Testing effectiveness (Phase 2)Study completedNCT02283320
What this trial is testing

BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer

Who this might be right for
KRAS Positive Patients With Non-small Cell Lung CancerSquamous Cell Non-small Cell Lung Cancer
BIND Therapeutics 69